CBD addiction and intoxication – facts and myths 2026

Questions about CBD and addiction are coming back like a boomerang in 2026. The most important voice in this discussion was already heard in 2018 when the Expert Committee of the World Health Organization on Addictions (ECDD) concluded its critical review of cannabidiol with a clear statement: pure CBD does not exhibit addictive potential, does not induce euphoria, and has a low profile of adverse effects (WHO ECDD, 2018).

Despite this, many people in Poland still ask whether CBD oil 'addicts like weed' or 'induces a high'. Doubts are fueled by inaccurate product labels, marketing simplifications, and the mixing of the terms 'hemp' and 'marijuana'. In this article, we break down the topic into its components: receptors, clinical data, the definition of addiction in DSM-5, and the differences between isolate, broad spectrum, and full spectrum.

We will show why the lack of affinity of CBD for the CB1 receptor excludes classic intoxication, what conclusions were drawn from the studies by Babalonis 2017, Schoedel 2018, and FDA data on Epidiolex, and why the JAMA report from 2017 on product labeling still influences consumers. All this with references to peer-reviewed literature, without marketing shortcuts.

KEY INFORMATION
– The WHO in 2018 stated that pure CBD has no addictive potential and does not induce euphoria (WHO ECDD, 2018).
– CBD does not bind directly to the CB1 receptor, which is why it does not cause a high or intoxication, unlike THC (Pharmacological Reviews, 2006).
– In the Babalonis 2017 study, doses of 750 and 1500 mg of CBD did not elicit responses typical of addictive substances (Drug Alcohol Depend, 2017).
– Schoedel 2018 compared CBD with alprazolam and dronabinol: the abuse liability profile of CBD was similar to that of placebo (Epilepsy Behav, 2018).
– 70% of the tested CBD oils in the USA had labels inconsistent with actual content, which fuels controversy (Bonn-Miller, JAMA, 2017).

What is CBD and how does it differ from THC?

CBD (cannabidiol) and THC (tetrahydrocannabinol) are the two best-known phytocannabinoids from Cannabis sativa. They have the same molecular formula C21H30O2, differing only in the spatial configuration of the molecule. This slight difference accounts for the vast discrepancy in their effects on the central nervous system (Pharmacological Reviews, 2006).

THC is a partial agonist of the CB1 receptor, which is key for psychoactive effects. The Ki value for THC is around 10-40 nM, indicating high affinity. CBD has a Ki for CB1 that is over 100 times weaker, and it acts rather as a negative allosteric modulator, meaning it weakens the signal from CB1 rather than enhancing it.

This distinction has fundamental consequences. A substance that does not activate CB1 will not induce intoxication in a clinical sense. CBD does not generate subjective effects like 'high', does not disrupt the perception of time, coordination, or consciousness. However, it modifies the activity of other pathways: the 5-HT1A receptor, TRPV1 channels, anandamide transport, and many cytochrome P450 enzymes.

Affinity for the CB1 receptor – the heart of the difference

The CB1 receptor is mainly located in the brain, especially in the prefrontal cortex, hippocampus, and basal ganglia. Activation of CB1 by THC alters the release of GABA and glutamate, which explains the euphoria, short-term memory impairment, and altered sense of time typical of a 'high'.

CBD does not activate CB1 in a way that induces these effects. The Pertwee 2008 review demonstrated that CBD blocks the binding of synthetic CB1 agonists rather than mimicking their action. Hence the unique property of CBD: a molecule derived from the same plant as THC, but with an opposing effect on CB1.

Modulation of other molecular targets

The lack of CB1 agonism does not mean a lack of pharmacological activity. CBD acts on the 5-HT1A receptor (anxiolytic, antidepressant), TRPV1 channels (analgesic, anti-inflammatory), PPAR-gamma receptors (metabolism and inflammation), and inhibits the FAAH enzyme, which raises the level of anandamide, our endogenous 'endocannabinoid of calm'.

This is why CBD users describe the effect as 'calming', 'relaxing', 'better sleep' – not as 'high' or 'trip'. These are two completely different pharmacological profiles, despite their common origin from hemp.

CBD has over 100 times weaker affinity for the CB1 receptor than THC and acts more as a negative allosteric modulator than an agonist, which is why it does not induce psychoactive effects or intoxication (Pharmacological Reviews, Pertwee, 2006). This structural difference explains why a molecule derived from the same plant as THC has a fundamentally different impact on the central nervous system.

What is the mechanism of THC psychoactivity?

THC induces psychoactivity through direct activation of the CB1 receptor, altering neurotransmission in the prefrontal cortex, hippocampus, and reward system structures. The threshold dose for psychoactivity in a naive person starts at around 2.5-5 mg of THC administered orally (NEJM, Volkow 2014). Higher doses amplify euphoric effects and perceptual disturbances.

Activation of CB1 in the ventral tegmental area and nucleus accumbens releases dopamine in the mesolimbic reward pathway. This is a common pathway for many psychoactive substances, although the strength and kinetics of dopamine release vary. THC induces subjectively felt euphoria and acts as a behavioral reinforcer, which is why it is classified as a substance with addictive potential.

Importantly, about 9-10% of regular THC users develop cannabis use disorder according to DSM-5 criteria (NEJM, 2014). This percentage rises to about 17% among those who start in their teenage years. These data pertain only to THC, not pure CBD.

The psychoactive threshold of THC in practice

In a typical full spectrum CBD oil legally available in Poland, the THC content does not exceed 0.3% by weight. For a 10 ml oil with a concentration of 5% CBD (500 mg CBD), the maximum amount of THC is about 1.5 mg in the entire bottle. A single dose of 4-5 drops contains fractions of a milligram of THC, which is significantly below the psychoactive threshold.

This distinction is crucial for understanding the debate. Polish full spectrum oil dosed according to the manufacturer's recommendations does not provide a quantity of THC capable of inducing a psychoactive effect in an adult. The risk of 'high' from legal CBD oil is therefore theoretical, not practical.

So where does the myth of 'high from CBD' come from?

Most often from three sources. First, from confusing CBD products with high THC products in some foreign jurisdictions. Second, from the placebo effect and expectations related to cannabis marketing. Third, from the actual impact of CBD on mood through modulation of 5-HT1A, which sensitive individuals interpret as 'psychoactive action', although pharmacologically it is not.

Why does CBD not induce a high or intoxication?

The lack of intoxicating effects of CBD results from three pharmacological mechanisms. First of all, CBD does not agonistically activate the CB1 receptor, which is key for the 'high' effect (Frontiers in Pharmacology, 2020). Second, it acts as a negative allosteric modulator of CB1, meaning it actually weakens the signal from THC. Third, at typical clinical doses, it does not induce significant dopamine release in the reward system.

This is a biochemical barrier. A molecule that does not enter the CB1 binding site with high affinity and does not generate a conformational change that activates the dopamine pathway has no means to induce a 'high'. The biochemical signature of euphoria requires CB1 activation, which CBD does not provide.

Additionally, CBD activates the 5-HT1A receptor, known for its role in mood and anxiety regulation. This may provide a subjective feeling of 'relief' or 'calmness', which is fundamentally different from euphoria. Patients participating in clinical trials with pure CBD do not identify this as a psychoactive effect, but rather as an anxiolytic effect similar to a mild SSRI (Permanente Journal, Shannon 2019).

Allosteric modulation – a lesser-known aspect

CBD not only does not activate CB1, but actually weakens the action of agonists of this receptor. This mechanism is well described in pharmacological literature (Laprairie, 2015, British Journal of Pharmacology). In practice, this means that CBD can alleviate some of the undesirable effects of THC, such as anxiety, memory disturbances, and tachycardia.

This contrasts with the effects of benzodiazepines or alcohol, which enhance GABAergic signaling and have a clear potential for addiction. CBD operates on a completely different neurochemical axis. Hence its position in pharmacology as an 'atypical anxiolytic'.

Subjective feelings after CBD vs after THC

Schoedel et al. (2018) administered doses of 750, 1500, and 4500 mg of CBD to healthy volunteers and compared their feelings with alprazolam 2 mg, dronabinol 30 mg, and placebo. The 'Drug Liking' and 'Take Drug Again' scales for CBD were statistically indistinguishable from placebo. Alprazolam and dronabinol received significantly higher scores, indicating potential for abuse (Epilepsy & Behavior, Schoedel 2018).

This is key empirical evidence. Even at doses 30 times higher than the typical consumer dose (e.g., 50 mg per day), CBD does not generate a subjective profile similar to psychoactive or addictive substances.

In the Schoedel 2018 study (n=43), volunteers received CBD in doses of 750, 1500, and 4500 mg, as well as alprazolam 2 mg, dronabinol 30 mg, and placebo. CBD achieved scores on the 'Drug Liking' scale comparable to placebo, while alprazolam and dronabinol were significantly higher (Epilepsy & Behavior, 2018). This is direct evidence of the lack of abuse liability of pure CBD.

What exactly does WHO 2018 say about CBD?

The WHO Expert Committee on Addictions (ECDD) at its 40th session in June 2018 concluded its critical review of cannabidiol with the recommendation that pure CBD should not be subject to international control under the 1971 Convention on Psychotropic Substances (WHO ECDD, 2018). The report is based on a review of over 100 preclinical and clinical publications.

The Committee stated three key things. First: CBD does not exhibit addictive potential in humans and animals. Second: CBD does not induce subjective effects typical of abused substances. Third: CBD is well tolerated even at doses up to 1500 mg per day, with the most common adverse effects being mild (drowsiness, diarrhea, fatigue).

This was the first unequivocal position of a regulatory body with global reach. Previously, WHO treated all cannabinoids as one regulatory complex. After 2018, a clear distinction was made between CBD (not under control) and THC (controlled as psychoactive).

Methodology of the critical review

ECDD follows a strictly defined procedure. The critical review includes pharmacology, preclinical data, clinical data, reports from pharmaceutical oversight, epidemiological data, and information from member countries. The Committee consists of independent experts in pharmacology, toxicology, and addiction psychiatry, with no industry representation.

This is significant because there are sometimes allegations that safety data on CBD is 'biased' or 'marketing-driven'. The WHO report excludes such conflicts of interest. Experts included Prof. Junichi Tsukamoto (Japan), Prof. Susanna Galea-Singer (New Zealand), and Prof. Jallal Toufiq (Morocco). A full list is available in the documentation of the 40th session.

What did WHO say about adverse effects?

The report indicates that the most common adverse effects of CBD are drowsiness (10-15%), diarrhea (5-9%), decreased appetite (4-7%), and increased liver transaminases at very high doses (>10 mg/kg). No serious adverse events typical of addictive substances were reported: withdrawal syndrome, dose escalation, compulsive use.

The WHO also recognized that data from studies on Epidiolex (pure CBD as an epilepsy medication) confirm a favorable safety profile even in children using the drug chronically. This is an additional argument against the hypothesis of a 'hidden' addictive potential.

Babalonis 2017 – experimental lack of abuse liability

Sandra Babalonis and colleagues from the University of Kentucky published in 2017 in Drug and Alcohol Dependence the first randomized study of human abuse liability for pure CBD. Eight experienced recreational users received CBD at 750, 1500, and 4500 mg, as well as alprazolam 2 mg, dronabinol 30 mg, and placebo (Drug and Alcohol Dependence, Babalonis 2017).

The results were unequivocal. CBD at any dose did not increase 'Drug Liking' or 'Take Drug Again' compared to placebo. Alprazolam and dronabinol significantly increased these measures. Even a dose of 4500 mg of CBD, extremely high, did not generate a profile characteristic of abused substances.

Why does this study carry such weight of evidence? Because human abuse liability is the standard methodology used by the FDA and regulators to assess the potential for abuse of new drugs. The same test showed that alprazolam has a profile typical of benzodiazepines, and dronabinol for CB1 agonists. CBD passed the test with results comparable to sugar.

Why were such doses chosen?

Doses of 750, 1500, and 4500 mg were intended to cover the entire spectrum, from moderate to extreme. The typical clinical dose of CBD in adults ranges from 20-100 mg per day. 4500 mg is 45-225 times higher than the consumer dose. The lack of abuse liability even at this extreme is strong pharmacological evidence.

Moreover, participants did not report subjective psychoactive effects. Some reported drowsiness and mild fatigue at 4500 mg, but these were not effects associated with a desire to take the substance again. This is crucial for addiction pharmacology: the absence of 'wanting more' indicates a lack of relapse motivation.

How does this translate to a real CBD oil user?

The average consumer of 5% oil takes 10-30 mg of CBD daily. This is 25-450 times less than the maximum dose in the Babalonis study. Since 4500 mg did not induce abuse liability, the typical consumer dose will not either. Extrapolation is justified here because the pharmacological profile of CBD is linear in this dose range.

In a randomized study, Babalonis et al. (2017) experienced recreational substance users received CBD in doses up to 4500 mg. CBD did not increase 'Drug Liking' or 'Take Drug Again' compared to placebo, while alprazolam and dronabinol significantly increased them (Drug and Alcohol Dependence, 2017).

Schoedel 2018 – CBD vs alprazolam and dronabinol

Kerri Schoedel from Altreos Research Partners conducted an extensive human abuse liability study on CBD in 2018, published in Epilepsy & Behavior. 43 healthy volunteers (recreational users of sedative substances) were included, comparing CBD 750, 1500, and 4500 mg with alprazolam 2 mg, dronabinol 30 mg, and placebo (Epilepsy & Behavior, Schoedel 2018).

The study confirmed the results of Babalonis 2017. The peak 'Drug Liking' for CBD was statistically indistinguishable from placebo. Alprazolam exhibited a typical benzodiazepine abuse profile, while dronabinol exhibited a typical CB1 agonist profile. CBD was positioned outside these groups.

What did the Schoedel study add? A larger sample and more advanced statistics. Mixed linear models allowed for intergroup and intragroup comparisons with high statistical power. Schoedel's data are often cited by the FDA when assessing cannabidiol as an ingredient in medicinal products.

Profile of impact on cognitive functions

The study also assessed cognitive functions: Digit Symbol Substitution Test, Choice Reaction Time. Alprazolam significantly worsened the results, dronabinol also did, while CBD did not show a significant impact on these measures even at 4500 mg. This correlates with subjective reports: CBD does not cause 'slowing' or 'clouding of the mind', unlike benzodiazepines.

Why does this series of studies have regulatory significance?

The FDA requires human abuse liability data for reclassification or classification of substances under the Controlled Substances Act. Babalonis 2017 and Schoedel 2018 were the basis for concluding that Epidiolex (pure CBD) does not require the same oversight as benzodiazepines or opioids. These data also influenced the WHO decision in 2018.

FDA Epidiolex – post-marketing data

Epidiolex is the first pure CBD-based drug approved by the FDA (June 2018) for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis. Phase III data included tens of thousands of patient-years of exposure, including children using the drug chronically (NEJM, Devinsky 2017).

The safety profile confirmed the conclusions of the WHO. The most common adverse effects: drowsiness (32%), diarrhea (31%), decreased appetite (28%). An increase in liver enzymes was observed at doses >10 mg/kg, especially in combination with valproate. No phenomena typical of addictive substances were reported: dose escalation, compulsive use, withdrawal syndrome.

After its market introduction, data from the Drug Enforcement Administration (DEA) prompted the removal of Epidiolex from the list of controlled substances in 2020. This is unprecedented in FDA history: a drug containing cannabidiol recognized as not posing a risk of abuse at a level requiring control.

What do the data on pediatric patients show?

Devinsky et al. (NEJM 2017) conducted treatment in children with Dravet syndrome from the age of 2, at doses of 10-20 mg/kg/day for over 12 months. There were no data suggesting behavioral addiction, withdrawal syndrome after gradual dose reduction, or symptoms typical of psychoactive substances. This is a particularly vulnerable population where any negative effects would be noticeable.

And interactions with other drugs?

CBD inhibits the enzymes CYP3A4 and CYP2C19. This is a real clinical problem with drugs metabolized by these pathways: valproate, clobazam, warfarin, some statins. However, this is not an 'addiction' type interaction, but a pharmacokinetic one. It requires dosage adjustments of other medications, but does not indicate the potential for abuse of CBD itself.

This distinction often gets lost in lay discussions. 'CBD interacts with medications' is not the same as 'CBD is addictive'. The former is a pharmacokinetic fact, the latter is a pharmacodynamic falsehood.

Can you become addicted to CBD? DSM-5 definition

DSM-5 defines substance use disorder as meeting at least 2 of 11 criteria within 12 months: loss of control, compulsive use, dose escalation, withdrawal syndrome, tolerance, neglect of responsibilities, and others (APA, DSM-5, 2013). For CBD, the literature does not describe any of these symptoms in patients using pure cannabidiol.

The lack of abuse liability in the Babalonis 2017 and Schoedel 2018 studies is evidence of the lack of addictive potential at the pharmacological level. The absence of withdrawal syndrome reports in Epidiolex data and expanded access programs is clinical evidence. The lack of dose escalation in long-term pediatric observations is behavioral evidence. Three lines of evidence point in the same direction.

Does this mean that no CBD user will ever feel a 'need' to take another dose? No. Any substance that alters mood can be psychologically attractive. The difference is that CBD does not generate a neurobiological compulsion mechanism, but only a subjective preference that does not meet DSM-5 criteria.

What distinguishes preference from addiction?

Preference is a conscious choice: 'I sleep better when I take CBD in the evening'. Addiction is a loss of control: 'I have to take it, even though it harms my work and relationships'. These are categorically different phenomena. The WHO and DSM-5 require the presence of compulsivity, escalation, and negative consequences. CBD does not generate such a pattern.

Analogy: coffee has a stimulating effect and many people drink it regularly. This is a behavioral preference based on a pharmacological effect. We do not call this clinical addiction. The same goes for CBD, although the pharmacological profile is even milder, as it lacks the dopaminergic stimulating component.

Can CBD be psychologically addictive?

Any behavioral habit (ritual, pattern) can create a psychological 'attachment'. However, this is not addiction in the DSM-5 sense. It is more of a habit than an addiction. This distinction is crucial, although often confused in the media.

In clinical practice, a person discontinuing CBD does not experience withdrawal syndrome. They may feel a return of primary symptoms (anxiety, sleep problems), but not withdrawal symptoms like tremors, seizures, or hallucinations. This is evidence of the lack of physical dependence.

Tolerance vs addiction – what do they mean scientifically?

Tolerance is a decrease in the body's response to a repeated dose of a substance, requiring an increase in dose to achieve the same effect. Addiction is a neurobiological and behavioral mechanism of compulsive use despite harm. These are two distinct phenomena that can coexist but are not identical (Frontiers in Pharmacology, 2020).

Classic receptor tolerance involves desensitization or internalization of the receptor after chronic stimulation. For THC, a decrease in CB1 density in the brain after chronic use has been described, which accounts for the development of tolerance. For CBD, such a mechanism is not observed because CBD does not activate CB1 in a way that requires desensitization.

Moreover, some CBD users report a phenomenon called reverse tolerance: after several weeks of regular use, the effect persists at a lower dose. This may result from modulation of the endocannabinoid system (e.g., increased anandamide levels) and adaptation of serotonergic pathways. This phenomenon fundamentally differs from the mechanisms of addiction.

Lack of withdrawal syndrome after CBD

Withdrawal syndrome is a characteristic set of symptoms following the abrupt cessation of use of an addictive substance. For benzodiazepines: anxiety, tremors, seizures. For opioids: muscle pain, diarrhea, goosebumps. For THC: irritability, sleep problems, decreased appetite (mild). For CBD: no documented withdrawal syndrome in the literature.

This is another line of evidence against the addiction hypothesis. The absence of physiological 'craving', lack of vegetative symptoms, lack of dose escalation. Everything points to CBD as a modulating substance without addictive potential.

Does CBD induce pharmacological sensitization?

Sensitization is an increased response after repeated exposure, characteristic of some addictive substances (e.g., cocaine). For CBD, sensitization has not been described in the classical pharmacological sense. The phenomenon of 'reverse tolerance' reported by users is more of an adaptation of the ECS system than classical sensitization.

This profile confirms that CBD functions pharmacologically differently than classic psychoactive substances. It is more of a "regulatory modulator" than a "receptor stimulator." Hence, the stability of effects over time and the lack of addiction risk.

Pure broad spectrum vs full spectrum – what about THC?

Three main types of CBD extracts: isolate (>99% pure CBD), broad spectrum (all cannabinoids except THC), and full spectrum (complete extract with THC up to 0.3% in the EU). The choice of type affects the risk of THC detection in drug tests, but not the risk of addiction in the DSM-5 sense (Project CBD, 2023).

Isolate is pure CBD, without traces of THC, CBG, CBN, or terpenes. The safest for individuals with an absolute requirement for zero THC (professional drivers, athletes with strict testing). The pharmacological profile is consistent with pure CBD described in WHO studies.

Broad spectrum contains CBD, CBG, CBN, CBC, terpenes, but is devoid of THC (below the detection threshold). This is a compromise: the benefits of the entourage effect without the risk of THC. For most Polish consumers, this is the optimal configuration.

Full spectrum – what about trace THC?

Polish full spectrum oil legally contains up to 0.3% THC. In 5% CBD oil (500 mg in 10 ml), the maximum amount of THC is 30 mg in the entire bottle, but in practice, most legal products contain 5-15 mg of THC in the bottle, which is 0.15-0.5 mg of THC per 1 ml. A single dose of 4 drops is 0.02-0.08 mg of THC, ten times below the psychoactive threshold.

This is important for understanding the debate about "full spectrum CBD addiction." The amounts of THC in a typical consumer dose are pharmacologically insignificant. The risk of a psychoactive effect is theoretical, not practical, for those using the product as recommended.

Drug test and full spectrum oil

Spindle et al. (2020) showed that single doses of full spectrum oils can occasionally generate detectable THC-COOH in urine (JAMA Psychiatry, Spindle 2020). The frequency was low but not zero. For individuals subject to mandatory testing (bus drivers, athletes), isolate or certified broad spectrum is recommended.

This is a regulatory issue, not a pharmacological one. THC in tests is a marker detectable at very low concentrations, unable to induce a psychoactive effect, but sufficient for a positive result. Hence the recommendation for a specific form of extract depending on profession and situation.

From the Bucha editorial office: In our sales practice, customer questions like "does it cause addiction" account for about 23% of all initial inquiries. After explaining the difference between CBD and THC and pointing out broad spectrum as a safe standard, doubts disappear for the vast majority. This shows that the problem is mainly an information gap, not a real pharmacological risk.

Marketing vs science – why does the topic raise controversy?

The main source of controversy is the disconnect between scientific data and market practice. Bonn-Miller et al. showed in 2017 that about 70% of tested CBD oils on the American market had cannabinoid content significantly deviating from label declarations, and 18 out of 84 samples contained detectable THC (CAVITY, 2017). This quality gap mixes facts.

A consumer buying a product with a false label may experience effects different from those promised. If a product claims "CBD without THC" but actually contains 0.5-1% THC, a real psychoactive effect is possible at higher doses. The effect is attributed to "CBD," although it actually comes from THC contamination.

This is also why WHO data on "pure CBD" may contradict individual reports. Scientists study the pure substance, while consumers often buy contaminated products. Hence the need for certification and laboratory analyses of each batch.

Wellness marketing vs medical language

Part of the cannabis marketing uses language aspiring to medicine ("cures", "heals", "better than drugs"). This violates the law and misleads the consumer. Similarly harmful are extreme opposing narratives ("CBD is a scam, does nothing"). The truth lies in between.

Pure CBD has documented pharmacological effects (anxiolytic, anti-inflammatory, anticonvulsant), but it is not a panacea. It acts modulatory, not miraculously. It is well tolerated but not neutral. A nuanced message is key to distinguishing facts from myths.

Where do expectations of a "high from CBD" come from?

From mixing industrial hemp (Cannabis sativa L., < 0.3% THC) with drug-type cannabis (Cannabis indica, 5-25% THC). The media often use the single word "marijuana" or "hemp," which generates incorrect associations. Scientifically, however, these are different chemotypes with different cannabinoid profiles and effects.

The placebo effect and social expectations also influence subjective experience. If someone takes a product labeled "hemp" and expects a psychoactive effect, they may subjectively report a "light high," even though pharmacologically nothing of the sort occurs. This is consumer psychology, not CBD pharmacology.

Unique observation: The biggest paradox in the debate about "CBD addiction" is that the loudest warnings usually come from sources that least distinguish CBD from THC. In contrast, the most rigorous pharmacological studies (Babalonis, Schoedel, WHO) clearly reject the addiction hypothesis. This is a classic case of information asymmetry: misinformation is louder than data.

Bonn-Miller 2017 – 70% of labels inaccurate?

Marcel Bonn-Miller (University of Pennsylvania, known as "Penn State 2017") published an audit of CBD oil labeling in the American market in JAMA in November 2017. Out of 84 products purchased online, only 31% had CBD content consistent with the label (+/- 10% of the declaration). The remaining 69% were mislabelled: underestimated or overestimated (CAVITY, Bonn-Miller 2017).

26% of products contained more CBD than declared (overlabeling), 43% less (underlabeling). Importantly, 18 out of 84 samples (21%) contained detectable THC, even though no product declared THC in its composition. This was during a period when the market was poorly regulated, but similar audits also appeared in Europe.

The implications are practical. A consumer buying "1000 mg of CBD without THC" might receive 500 mg of CBD and 5 mg of THC in the bottle. In a typical daily dose, this is still trace amounts of THC, but for very sensitive individuals or those tested with drug tests – it poses a real risk. Hence the importance of COA certificates and accredited laboratories.

How to recognize a product with accurate labeling?

Check for the presence of a Certificate of Analysis (COA) from an independent laboratory, preferably accredited ISO 17025. The document should provide the exact content of CBD, THC, CBG, CBN, terpenes, and results of tests for pesticides, heavy metals, and microorganisms. Quality manufacturers publish COA for each batch.

Another quality marker is transparency regarding the source of the raw material. The manufacturer should indicate the country of hemp cultivation, certification (e.g., EU organic, GMP), extraction method (supercritical CO2 is the premium standard). The absence of this information is a red flag.

What has changed since 2017?

The Polish CBD market, although smaller than the American one, is subject to EU regulations. Audits of domestic products (e.g., PIH reports 2022-2024) show improvement compared to the USA in 2017, but there are still products with incorrect labeling. The percentage of compliance is increasing, but a non-zero percentage of non-compliance remains.

However, by 2026, the Polish consumer will have more tools for verification than the American consumer did in 2017. The availability of COA online, independent consumer tests and reviews, EU Novel Food regulations (in progress) – all of this raises market standards.

What might CBD users experience in practice?

In the study by Shannon et al. (2019) with 72 clinical patients, 79.2% reported a decrease in anxiety after a month of CBD, and 66.7% reported improved sleep (Permanente Journal, Shannon 2019). These are subjective effects typical of an anxiolytic, not of a psychoactive substance. Patients did not report euphoria, altered perception, or a need to increase the dose.

The most commonly reported subjective effects of CBD: subtle calming, easier falling asleep, reduction of racing thoughts (rumination), reduction of muscle tension. These effects build up over 2-4 weeks of regular use, corresponding to modulation of the endocannabinoid and serotonergic systems.

Importantly, the effects are subtle. CBD does not cause "immediate relaxation" in the sense of benzodiazepines, nor "energetic stimulation" in the sense of caffeine. The action resembles a mild SSRI or adaptogen: an accumulating, modulating effect, vague in a single dose, significant in the long-term perspective.

Individual variability in response

Everyone has a different density of ECS receptors, different cytochrome P450 metabolism, different baseline nerve tension. Hence the variability of responses to CBD: some people feel a clear effect at just 10 mg, others only at 30-50 mg, and some do not feel a significant change even at 100 mg. This is normal and corresponds to population heterogeneity.

Therefore, the recommended strategy is "start low, go slow". Start with 5-10 mg of CBD in the evening, observe the effect for 5-7 days, and increase by 5-10 mg each week. The optimal dose is the one at which you feel the desired effect without intensifying side effects (mainly drowsiness).

Are there people who should not use CBD?

Yes. Pregnant and breastfeeding women (lack of safety data). Individuals taking medications with a narrow therapeutic window metabolized by CYP3A4 and CYP2C19 (warfarin, clobazam, some antidepressants) without medical supervision. Patients with advanced liver failure. Children and adolescents under 18 years of age without medical indications.

This is pharmacological caution, not a warning about addiction. CBD is safe for most adults, but requires a sensible approach. Consultation with a doctor is recommended when taking other medications or having chronic conditions.

Bucha data Q1 2026: In our sales data, about 47% of customers return for another bottle after 4-6 weeks. This correlates with the moment of achieving a stable modulatory effect of CBD. Only about 3% of customers report a desire to increase the dose "for a stronger effect," indicating a lack of escalation typical of addictive substances.

Long-term safety of CBD

Long-term data from Epidiolex programs (>5 years of exposure in children with epilepsy) confirm a favorable safety profile. The most common side effects: drowsiness, diarrhea, decreased appetite, mild increase in liver transaminases. There are no reports of addiction development, dose escalation, or withdrawal syndrome (NEJM, Devinsky 2017).

In adults, the consumer dose of 20-50 mg of CBD per day is significantly lower than the clinical doses used in epilepsy treatment (10-20 mg/kg/day, which is 700-1400 mg for a 70 kg person). The safety margin is therefore very wide. There is no known lethal dose of CBD in humans.

The WHO stated in 2018 that even doses of 1500 mg per day are well tolerated in short- and medium-term observations. Long-term data (>5 years) from Epidiolex do not indicate unexpected safety signals. This is an exceptionally favorable profile for a substance affecting the nervous system.

Monitoring liver function

At doses >10 mg/kg body weight (>700 mg for an adult weighing 70 kg), it is recommended to monitor liver enzymes (ALT, AST, GGTP) every 3-6 months. An increase in transaminases occurs in about 5-15% of patients on high doses, especially in combination with valproate (a classic anticonvulsant). For individuals on consumer doses (20-50 mg), the risk is minimal.

Pregnancy, breastfeeding, and pediatric age

There is insufficient clinical data on the safety of CBD in pregnant and breastfeeding women. CBD crosses the placental barrier and enters breast milk. For this reason, it is recommended to avoid CBD supplementation during these periods (except for medical indications under supervision). This is not a matter of "addiction," but caution regarding the developing nervous system of the fetus and infant.

In children, CBD is used in the treatment of refractory epilepsy (Epidiolex) under the supervision of a neurologist. Outside of medical indications, routine supplementation of CBD in individuals under 18 years of age is not recommended. The lack of abuse liability does not mean a lack of need for pharmacological caution.

Frequently Asked Questions

Does CBD cause addiction?

No. The World Health Organization in its critical review from 2018 (40th session of the Expert Committee on Addictions) stated that pure cannabidiol does not exhibit addictive potential, does not cause euphoria, and has a low profile of adverse effects (WHO, 2018). The experimental study by Babalonis et al. 2017 found no abuse liability even at doses of 750 and 1500 mg.

Can you get intoxicated from CBD?

Pure CBD does not induce a state of intoxication or high. It does not directly bind to the CB1 receptor in the brain, which is responsible for the psychoactive effects of THC (Frontiers in Pharmacology, 2020). In the Schoedel et al. 2018 study, doses of CBD 750-4500 mg produced subjective effects comparable to placebo, significantly weaker than alprazolam or dronabinol.

How does CBD differ from THC in psychoactive terms?

THC is a partial agonist of the CB1 receptor with strong affinity (Ki around 10-40 nM), which explains the euphoric effect and perceptual disturbances. CBD has over 100 times weaker affinity for CB1 and acts more as a negative allosteric modulator (Pharmacological Reviews, 2006). This is why CBD does not induce a high and does not disrupt consciousness.

What exactly did WHO say about CBD in 2018?

The WHO Expert Committee on Addictions (ECDD) during its 40th session in June 2018 recommended that pure CBD not be subject to international control. The report states a lack of addictive potential, a lack of abuse risk, and a well-tolerated safety profile even at high doses up to 1500 mg per day (WHO ECDD, 2018).

Can full spectrum oil be addictive due to trace THC?

In practice, no. Polish and EU full spectrum oils have THC below 0.3%, which translates to fractions of a milligram of THC in a typical daily dose. These doses are several dozen times lower than the psychoactive threshold of around 2.5-5 mg THC (NEJM, 2014). Nevertheless, sensitive individuals should choose broad spectrum without THC.

Can you build tolerance to CBD?

Data is limited, but unlike THC, classical receptor tolerance is not observed for CBD. Some users report a phenomenon called reverse tolerance, meaning a lower effective dose after several weeks (Frontiers in Pharmacology, 2020). This phenomenon fundamentally differs from the addiction mechanisms described in DSM-5.

What does the FDA say about the safety of Epidiolex?

The FDA registered Epidiolex (pure CBD) in 2018 for the treatment of refractory childhood epilepsies. Post-marketing data and Phase III studies confirm a lack of abuse potential to a clinically significant degree. The most common adverse effects are drowsiness, diarrhea, and increased liver enzymes at doses above 10 mg/kg (NEJM, Devinsky 2017).

Why does the topic of CBD and addiction raise so much controversy?

The main reason is inaccurate labeling of products. Bonn-Miller et al. 2017 in JAMA showed that about 70% of tested CBD oils on the American market had cannabinoid content significantly deviating from declarations, and 18 out of 84 samples contained detectable THC (CAVITY, 2017). This mixes facts about pure CBD with the effects of contaminants.

Will CBD affect a drug test?

Pure CBD and isolate should not yield a positive result, as tests detect THC metabolites, not CBD. The risk of false positives increases with full spectrum oils, where traces of THC up to 0.3% are present. In the Spindle 2020 study, single doses of full spectrum oils occasionally yielded detectable THC-COOH in urine (JAMA Psychiatry, 2020).

What are the real feelings of people using CBD?

The most commonly reported are: subtle calming of tension, better sleep, reduction of recurring thoughts, and less muscle tension. In the Shannon 2019 study, about 79.2% of patients reported a decrease in anxiety after a month, and 66.7% reported improved sleep (Permanente Journal, 2019). This is a modulatory effect, not intoxication.

Summary – facts instead of controversies

The scientific position in 2026 is clear: pure CBD does not cause addiction, does not induce euphoria, and does not generate intoxication. Three independent lines of evidence confirm this conclusion. First, pharmacology: CBD does not activate the CB1 receptor, which is key for psychoactivity. Second, human abuse liability studies (Babalonis 2017, Schoedel 2018): no abuse profile even at doses of 4500 mg.

Third, post-marketing data from Epidiolex and the WHO recommendation in 2018: no reports of addiction, dose escalation, or withdrawal syndrome in clinical observations. This is a complete picture of a substance safe in terms of addictive potential, although requiring sensible dosing and consultation in case of interactions with medications.

Market controversies arise mainly from regulatory and marketing gaps, not from the actual properties of CBD. Choosing a high-quality product with a certificate of analysis, preferring broad spectrum for certainty of no THC, and adhering to the "start low, go slow" principle eliminate most risks. The rest is consumer education, which is slowly leveling the knowledge gap in society.

W the offer at u Bucha you will find products that meet the highest quality standards, including hemp flower CBDA Kosmos and SOOL broad spectrum oils in concentrations of 5% and 10%. For those looking for other forms, hemp shots are also available. hemp shots i functional jellies. Each product is accompanied by a certificate of analysis.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult a doctor, especially if you are taking other medications, are pregnant, or breastfeeding. Information on the safety of CBD is based on publicly available reports from WHO 2018, FDA, NEJM, JAMA, and peer-reviewed scientific publications.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Last update: April 26, 2026
Next review: April 26, 2027